Susquehanna International Group’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q1 | – | Sell |
-21,900
| Closed | -$29K | – | 10987 |
|
|
2016
Q4 | $29K | Sell |
21,900
-34,500
| -61% | -$60K | ﹤0.01% | 9384 |
|
|
2016
Q3 | $118K | Buy |
56,400
+13,500
| +31% | +$26.7K | ﹤0.01% | 7878 |
|
|
2016
Q2 | $69K | Sell |
42,900
-600
| -1% | -$1.15K | ﹤0.01% | 8169 |
|
|
2016
Q1 | $42K | Sell |
43,500
-21,900
| -33% | -$21.4K | ﹤0.01% | 8704 |
|
|
2015
Q4 | $79K | Sell |
65,400
-51,800
| -44% | -$166K | ﹤0.01% | 8965 |
|
|
2015
Q3 | $871K | Buy |
117,200
+27,800
| +31% | +$213K | ﹤0.01% | 6057 |
|
|
2015
Q2 | $639K | Sell |
89,400
-17,000
| -16% | -$132K | ﹤0.01% | 7137 |
|
|
2015
Q1 | $914K | Sell |
106,400
-47,700
| -31% | -$427K | ﹤0.01% | 5931 |
|
|
2014
Q4 | $1.54M | Sell |
154,100
-142,900
| -48% | -$1.22M | ﹤0.01% | 4992 |
|
|
2014
Q3 | $2.94M | Buy |
297,000
+69,000
| +30% | +$1.02M | ﹤0.01% | 3935 |
|
|
2014
Q2 | $3.94M | Sell |
228,000
-25,500
| -10% | -$416K | ﹤0.01% | 3469 |
|
|
2014
Q1 | $4.5M | Buy |
253,500
+136,900
| +117% | +$2.65M | ﹤0.01% | 3043 |
|
|
2013
Q4 | $2.13M | Sell |
116,600
-251,200
| -68% | -$4.74M | ﹤0.01% | 4165 |
|
|
2013
Q3 | $9.86M | Sell |
367,800
-84,000
| -19% | -$1.8M | 0.01% | 1925 |
|
|
2013
Q2 | $8.34M | Buy |
+451,800
| New | +$7.98M | ﹤0.01% | 2008 |
|
Susquehanna International Group's RPRX Position: Q1 2018 in Review
Susquehanna International Group sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 91,976 shares — an estimated $61K sold.
Susquehanna International Group first reported a position in RPRX in Q2 2013 and held it in 12 quarters. The position peaked at $6.95M in Q3 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Susquehanna International Group reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Susquehanna International Group sold 91,976 Repros Therapeutics Inc. shares in Q1 2018, an estimated $61K.
- Susquehanna International Group first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 12 quarters.
- Susquehanna International Group's Repros Therapeutics Inc. position peaked at $6.95M in Q3 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Susquehanna International Group's 13F filing for Q1 2018, filed 15 May 2018.